Steroid receptor coactivator-2 (SRC-2) is a transcriptional coregulator that modulates the activity of many transcription factors. Levels of SRC-2 are elevated in endometrial biopsies from polycystic ovary syndrome patients, a population predisposed to endometrial cancer (EC). Increased expression of SRC-2 is also detected in neoplastic endometrium suggesting a causal link between elevated SRC-2 expression and the emergence of endometrial disorders that can lead to cancer. Here, we reveal that SRC-2 knockdown reduces EC cell proliferation and anchorage-independence. Additionally, SRC-2 is required to maintain cellular glycolytic capacity and oxidative phosphorylation, processes essential for EC cell proliferation. Importantly, SRC-2 is critical for the normal performance of the pentose phosphate pathway (PPP). Perturbation of the PPP due to loss of SRC-2 expression may result from the depletion of ribose-5-P isomerase (RPIA), a key enzyme of the PPP. As with SRC-2, RPIA knockdown reduces EC cell proliferation, which is accompanied by a decrease in glycolytic capacity and oxidative phosphorylation. Glucose metabolite tracking experiments confirmed that knockdown of SRC-2 and RPIA downregulates the metabolic rate of both glycolysis and the PPP, highlighting a novel regulatory cross-talk between glycolysis and the PPP modulated by SRC-2.
In the case of endometrial pathology, SRC-2 is increased, along with SRC-3, in the endometrium of patients with polycystic ovary syndrome [16] [17] [18] , a population characterized by an increased EC risk. Additionally, these two coregulators are elevated in hyperplastic and neoplastic endometrium [19] [20] [21] . Together these descriptive findings suggest a causative link between the expression of SRC-2 and SRC-3 and the emergence of endometrial pathologies that may give rise to cancer. This hypothesis is supported by observations in an SRC-2 overexpressor mouse model 22 , in which endometrium-targeted increased levels of SRC-2 led to an impairment of decidualization associated with hyperproliferation of endometrial epithelial cells which are the primary cells of EC origin 23 . Upregulated expression of SRC-2 in the murine endometrium also led to increased sensitivity to estrogen exposure which is one of the main risk factors of endometrial cancer 24 .
In this study, we show that SRC-2 is indispensable for proliferation and anchorage-independence of human EC cells. The reduction of proliferation following SRC-2 knockdown is tightly linked to SRC-2′s role as a metabolic regulator. Measurements of metabolite levels and metabolic flux analysis revealed that SRC-2 is required for maintenance of glycolytic capacity and performance of the pentose phosphate pathway (PPP), due in part to its regulation of ribose 5-phosphate isomerase A (RPIA), an enzyme of the PPP.
Results

Proliferation and anchorage-independence of EC cells is maintained by SRC-2.
To study the role of SRCs in the maintenance of EC cell proliferative capacity, each of the three SRCs was knocked down using siRNAs in three EC cell lines: Ishikawa 25 and HEC-1A 26 -isolated from a well-differentiated EC tumors; and AN3CA 27 -isolated from a EC metastasis (Fig. 1A, Supplemental Fig. S1 ). In a clonogenic cell survival assay, the survival and growth of EC cells plated at low density was tested. Reduction of SRC-2 levels, but not of SRC-1 or -3, led to a decrease in EC cell colony formation ability (Fig. 1B) . Because the clonogenic cell survival method assays both cell proliferation and anchorage-independence, both of these properties were tested independently in the following experiments. A DNA content-based proliferation assay revealed that the accumulation of EC cells over 3 days was decreased when SRC-2, but not SRC-1 or SRC-3, levels were down-regulated (Fig. 1C) . Testing the knockdown of SRCs in combination excluded the potential reciprocal compensation effects in the case of SRC-1 and SRC-3 knockdowns (Supplemental Fig. S2 ). As in the case of the proliferation assay, only SRC-2 knockdown caused a reduction of colony formation of cells plated in soft agar (Fig. 1D,E) , demonstrating that SRC-2 is indispensable for both EC cell proliferation and anchorage-independence.
SRC-2 is required to uphold glycolysis and generation of phosphopentoses in EC cells. Because
SRC-2 is crucial in maintaining the glycolytic capacity of decidualizing hESCs 12 , its role in EC cell metabolism was investigated. Lactate production (an output of glycolysis) which is measured by acidification of the medium was significantly decreased with SRC-2 knockdown ( Fig. 2A,B) . Specifically, both basal glycolytic capacity (measured before oligomycin treatment) and maximal glycolytic capacity (detected after oligomycin treatment) of EC cells were significantly reduced. Additionally, oxygen consumption, an output of oxidative phosphorylation (OXPHOS), was also significantly impaired following SRC-2 knockdown (Fig. 2C,D) .
In hESCs, SRC-2 regulates glycolysis by upholding the expression of PFKFB3 12 therefore the expression of PFKFB family members was tested first. Similarly as in the case of hESCs, SRC-2 knockdown in EC cells led to a moderate downregulation of PFKFB3 levels (Supplemental Fig. S3 ). In the case of other PFKFB family members, PFKFB1 transcripts were not detected by RT-qPCR, while no changes in PFKFB2 levels were found; PFKFB4 expression levels slightly increased with SRC-2 downregulation (Supplemental Fig. S3 ). Therefore due to the moderate opposing PFKFB3/4 expression changes, levels of metabolites of glycolysis, but also the tricarboxylic acid (TCA) cycle, and the pentose phosphate pathway (PPP) were assayed by liquid chromatography-mass spectrometry (LC-MS) (Fig. 2E) . The only significant change in metabolite levels was the reduction of PPP metabolites with SRC-2 knockdown. In particular, SRC-2 knockdown led to the decrease in levels of phosphopentoses (ribulose-5-P and ribose-5-P) and their downstream metabolites (i.e. nucleotides and nucleosides). Based on this result, the expression levels of enzymes of the PPP were measured. Only one of them, ribose-5-phoshate isomerase (RPIA), was both significantly and markedly reduced with SRC-2 knockdown (Fig. 2F) , suggesting a potential regulatory link between SRC-2 and the PPP in EC.
Expression of RPIA is required for EC cell proliferation. To determine whether the proliferative phenotype caused by reduction of SRC-2 levels is caused by the deregulation of RPIA, a clonogenic cell survival assay and a proliferation assay were performed in three EC cell lines. Knockdown of both SRC-2 and RPIA led to a significant downregulation of colony formation of the three EC cell lines (Fig. 3A) . A DNA-content based proliferation assay in Ishikawa cells also confirmed these findings (Fig. 3B) . Because reduction of SRC-2 levels resulted in a downregulation of nucleotide levels which could have led to a reduction of DNA synthesis and result in decreased cell proliferation, efficiency of DNA synthesis was evaluated. Both SRC-2 and RPIA knockdown caused a significant reduction in the population of cells in S-phase (Fig. 3C,D) as measured by levels of EdU incorporation over a period of 1 hour and by total DNA content, indicating a decrease of DNA synthesis. Interestingly, both SRC-2 and RPIA downregulation also caused an accumulation of cells in the G2 phase of the cell cycle, implying an impairment of EC cells entering into the mitotic phase of the cell cycle. On the other hand, synthesis of RNA was not affected by SRC-2 knockdown as measured by quantifying EU incorporation over 1 hour (Supplemental Fig. S4) . Therefore, the effect of nucleotide depletion was primarily affecting new DNA, as opposed to RNA synthesis, and may in part explain the role of SRC-2 and RPIA in controlling EC cell proliferation. Additionally, reduction of SRC-2 and RPIA led to elevated activation of caspase-3 and caspase-7 indicating increased apoptosis (Supplemental Fig. S5 ).
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The PPP and glycolytic pathways first diverge at the level of glucose-6-P (G6P). However, both pathways generate overlapping metabolites further downstream: fructose-6-P (F6P) and glyceraldehyde-3-P (GA3P). Therefore the generation of phosphopentoses and other PPP-specific phospho-sugars may occur either through the canonical PPP pathway or through the utilization of glycolytic metabolites further downstream. To distinguish between the two pathways of PPP phospho-sugar generation, 13 C tracking in cells treated with either 1-13 C-glucose or 6-13 C-glucose was performed (Fig. 5) . Measurements of 13 C-containing glycolytic metabolites generated from either 1-13 C-or 6-13 C-glucose revealed a downregulation of the glycolytic pathway when either SRC-2 or RPIA were knocked down, therefore confirming the findings of 13 C tracking shown in Fig. 4E . Measurements of 13 C-containing PPP phospho-sugars generated from 6-13 C-glucose also confirmed the PPP impairment when SRC-2 or RPIA levels were downregulated. These measurements of 13 C metabolites generated from 6-13 C-glucose do not however distinguish between the generation of PPP phospho-sugars through the canonical PPP pathway (from G6P) or from F6P and GA3P. Cells treated with 1-13 C-glucose will only generate 13 C PPP phospho-sugars through metabolizing F6P and GA3P (Supplemental Fig. S7) . Surprisingly, the levels of 13 C PPP phospho-sugars generated from 1-13 C-glucose were elevated when either SRC-2 or RPIA levels were reduced. This indicates that even though glycolysis and the PPP are overall impaired when SRC-2 or RPIA are knocked down, glycolysis still feeds back into the PPP and may even attempt to rescue diminished PPP phospho-sugar production. 
Discussion
The SRC family of transcriptional coregulators is implicated in the development of malignancies of multiple target tissues 28 . Due to their complex structure, SRCs are able to transactivate a broad spectrum of transcription factors and therefore are able to aid the survival and metastatic potential of cancer cells through a myriad of mechanisms 28, 29 . In the case of the endometrium, overexpression of SRC-2 has been shown in a mouse model to induce increased proliferation of endometrial epithelial cells. These increased levels of SRC-2 also resulted in hypersensitivity to estrogen exposure unopposed by progesterone, a major EC risk factor 22 . Shortly after the generation of the SRC knockout mouse models, it became evident that SRCs are important regulators of carbohydrate, lipid, and amino acid metabolism in many different cell types 30 . However, the link between metabolism, cancer, and SRC biology is yet to be fully understood. This knowledge-gap is important to address due to the connection between metabolic syndrome and cancer [31] [32] [33] . Metabolic syndrome is a cancer risk most highly associated with EC out of all cancer types 34 . In light of the increasing obesity epidemic 31 and EC incidence [3] [4] [5] , the investigation of mechanistic connections between metabolism and EC progression is urgently required for the development of more effective prevention and treatment strategies for this type of cancer. In the healthy endometrium, SRC-2 has been found to maintain glycolysis through the regulation of PFKFB3 12 . In EC cells, we also discovered that SRC-2 drives glycolysis, although the mechanism through which it does so may in part differ. We found that SRC-2 upholds the expression of PFKFB3 in EC cells but negatively regulates PFKFB4. The upregulation of PFKFB4 in response to SRC-2 knockdown may compensate for downregulation of PFKFB3. However the enzymatic activity of PFKFB4 is not as clearly defined as that of PFKFB3 [35] [36] [37] . Therefore, PFKFB4′s role in regulation of glycolysis in EC cells has to be further elucidated. Additionally, PFKFB4 has been recently shown to activate SRC-3 in breast cancer cells 38 which may also be a potential compensation mechanism to SRC-2 downregulation in EC cells. Despite the opposing PFKFB3 and PFKFB4 expression changes in EC cells, we found that SRC-2 controls both glycolytic and PPP capacity. Whether PFKFB3 or PFKFB4 deregulation is causative for glycolytic or PPP impairment remains an open question. A more likely reason for this metabolic phenotype as shown by our work here is the downregulation of RPIA. Knockdown of SRC-2 caused a reduction in the levels of RPIA (but not other glycolytic or PPP enzymes) while decreasing RPIA levels phenocopied the metabolic effects of SRC-2 knockdown. Therefore, we propose that RPIA is the most likely mediator of SRC-2′s role in controlling glycolysis and the PPP. The exact mechanism of regulation of RPIA by SRC-2 has to be further investigated in the future. Available SRC-2 ChIP-sequencing datasets derived from mouse 39 and human 40 cells indicate direct binding of SRC-2 to the RPIA promoter and enhancer region, However an indirect regulation mechanism of RPIA should also be considered.
Another consequence of SRC-2 and RPIA downregulation is a reduction of EC cell proliferation which may have been directly caused by the impairment of the PPP. This is due to the tight connection between DNA replication and PPP activity 41 . The reduction of nucleotide content upon SRC-2/RPIA knockdown most likely directly blocked DNA replication, leading to a decrease in EC cells entering S phase of the cell cycle. This would be in agreement with findings by other groups, who showed that RPIA maintains proliferation of pancreatic adenocarcinoma, hepatocellular carcinoma, and colorectal adenocarcinoma cells [42] [43] [44] . Importantly, reduction of DNA synthesis was also previously noted when RPIA levels were downregulated 42 . In our studies, both SRC-2 and RPIA knockdown caused an accumulation of cells in G2 phase of the cell cycle indicating an impairment in mitosis. The defect in mitosis may also have been caused by reduction of nucleotide levels. Not only were the levels of nucleotides reduced but also their relative ratios (adenosine monophosphate levels were more reduced than cytidine monophosphate levels) were changed which has been previously linked to genomic instability 45 . This could be the underlying cause of cells being also blocked in G2 and not being able to pass the G2/M checkpoint.
An important question that arose from our findings is: how does reduction of RPIA cause a decrease in activity of both PPP and glycolysis? We expected that when the rate of either glycolysis or the PPP was reduced, it would have led to a shunt of metabolites into the other pathway and vice versa. Even more striking were our findings from 13 C tracking in metabolites derived from 1-13 C-glucose which showed that even though both glycolysis and the PPP were downregulated, glycolytic metabolites were still shunted into the PPP further downstream. These results indicate that SRC-2, acting through RPIA, is a positive regulator of glycolysis and PPP. And because the output of glycolysis/PPP was reduced already at the level of glucose-6-P, the positive regulation of these pathways by SRC-2/RPIA may occur as early as at the level of glucose phosphorylation.
We did not detect any notable reductions of glycolytic enzyme expression as a result of SRC-2/RPIA knockdown. Therefore, maintenance of glycolysis/PPP could be mediated post-transcriptionally through a metabolite of the SRC-2-RPIA axis. The concept of metabolic intermediates as regulators of metabolic pathways is known. For example, fructose-2,6-P2 can activate PFK-1 and drive glycolysis forward or direct the metabolites towards the PPP 14, 15, 46 . Similarly, 2-P-glycerate and 3-P-glycerate have been shown to stimulate the synthesis of serine and inhibit the PPP 47 . Another possibility through which the PPP-glycolysis cross-talk may be regulated is modulation of signaling proteins by metabolic intermediates as it has been found in the case of ribulose-5-P and AMP-dependent kinase (AMPK) 48 . The exact mechanism through which the SRC-2-RPIA axis simultaneously regulates the activity of glycolysis and the PPP will have to be further investigated. Due to SRC-2′s function as a coregulator of many transcription factors, other cellular and metabolic processes controlling EC cells proliferation and survival should also be investigated. This is of further importance in light of reduced oxygen consumption after SRC-2 knockdown indicating a global metabolic effect of SRC-2 in EC cells.
Together, our findings have uncovered a novel role for SRC-2 in the regulation of glycolysis and the PPP through RPIA, which in part explains regulation of EC cell proliferation by SRC-2. Because the SRC family fulfils a broad number of functions in the cell, the full spectrum of processes regulated by SRC-2 in EC cells has to be further evaluated. In light of the developing field of SRC small molecule inhibitors (SMI) [49] [50] [51] [52] [53] and activators 54 , the targeting of SRC-2 in the uterus may be a promising avenue of EC prevention and treatment. The PPP has also been hypothesized and tested in vivo as a potential target for contraceptives delivered through intrauterine SCIENTIfIC REPORtS | (2018) 8:13134 | DOI:10.1038/s41598-018-31372-y devices 55 . A similar application of these types of inhibitors could be investigated in models of increased risk of EC development.
Material and Methods
siRNA transfections. All cell culture media and supplements were purchased from ThermoFisher Scientific.
Ishikawa cells were purchased from Sigma-Aldrich, HEC-1A and AN3CA cells were purchased from ATCC and maintained by Tissue Culture Core at Baylor College of Medicine. Due to increased number of experiments performed in Ishikawa cells, they were additionally confirmed by STR short tandem repeat (STR) analysis. Cells were plated into 6-well plates at 1-3 × 10 5 cells/well and transfected with siRNAs using Lipofectamine RNAiMAX. Per transfection, 60 pmol of siRNA was complexed 6 μl of Lipofectamine. Cells were incubated with siRNA-transfection reagent complexes over a period of 48 h (two consecutive 24 h transfections). siRNAs for knockdown for each gene of interest were delivered as a mix of 4 siRNAs: 1) Non-targeting, Dharmacon (Lafayette, CO), D-001810-10-20; 2) SRC-2 -Dharmacon, L-020159-00-0005; and 3) RPIA -Qiagen (Valencia, CA), GS22934.
Clonogenic cell survival assay. Following transfection, cells were plated into 12-well plates at 1000 cells per well and then grown for 8-10 days. The resulting colonies were stained with a 2.3% solution of crystal violet (Sigma-Aldrich, St. Louis, MO) for 15 min. To quantify colony formation, crystal violet was extracted with 10% acetic acid and its absorbance was measured at 590 nm.
Cell proliferation assay. Following transfection, cells were plated into 96-well plates at 1000 cells per well. 
RNA isolation and reverse transcriptase quantitative PCR (RT-qPCR).
From cultured cells, total RNA was isolated using RNeasy Plus spin columns (Qiagen, Valencia, CA) according to manufacturer's instructions. cDNA was prepared using SuperScript VILO cDNA Synthesis Kit (ThermoFisher, Waltham, MA) before RT-qPCR analysis was performed using TaqMan Universal Master Mix II with validated TaqMan Gene Expression Assays (ThermoFisher, Waltham, MA) listed in Supplemental Table ST1 . Resultant amplicons were quantitated using a QuantStudio 12K Flex Real-Time PCR System; 18S rRNA was used as an endogenous control.
Statistical analysis.
Results are presented as averages ± standard deviations and are a summary of a minimum of three experiments performed on separate days, except for 1) the flow cytometry experiments in which due to the high sensitivity of propidium iodide staining intensity to cell dilution, a representative experiment was presented (one experiment out of three; each containing three biological replicates); and 2) the mass-spectrometric measurements of metabolites which included 3-5 biological replicates collected and processed on the same day because of electronics variation across days. Normality of data was evaluated by inspecting quantile comparison plots. Equality of variances was analyzed using the Bartlett test of homogeneity of variances. Statistical analyses were performed with either ANOVA or Kruskal-Wallis rank sum test with post hoc analysis performed with Student's t-test, Tukey's range test, or Wilcoxon rank-sum test in R Studio (R Studio Inc., Boston, MA). Multiple comparisons were adjusted with the Holm method. p ≥ 0.05 were considered as non-significant differences while *p < 0.05, **p ≤ 0.01, and ***p ≤ 0.001 were considered significant.
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